Media

Keywords:Overseas Expansion Strategy, Compliance & Market Entry, Southeast Asia Opportunities

 

 

On January 9, 2026, the “Four-Chain Integration” Xiamen Biopharmaceuticals Overseas Expansion in Singapore: Market Opportunities and Practical Insights Exchange Conference was successfully held at the Xiamen Biopharmaceutical Industrial Park. The event was supported by the Consulate General of Singapore in Xiamen and jointly organized by SIG Global, the Xiamen Branch of Rongcheng Certified Public Accountants (Special General Partnership), the Xiamen Haicang Taiwanese Business Investment Zone Biopharmaceutical Association, and the Xiamen Branch of Bank of Communications. The conference focused on in-depth discussions on how Xiamen biopharmaceutical companies can establish clear overseas expansion pathways, reduce compliance risks, and achieve stable market entry amid a complex international environment.

Official Authoritative Insight: Grasp the Latest Trends in Singapore’s Economic Development

 

 

At the opening of the event, Mr. Zhuang Zhijia, Consul General of the Consulate General of Singapore in Xiamen, delivered a speech and shared insights on “Singapore’s Recent Economic Development.”

 

 

Drawing on Singapore’s recent economic performance and development trends, Consul General Zhuang Zhijia provided a macro-level analysis of Singapore’s positioning and advantages within the regional economic system, offering valuable guidance for Xiamen biopharmaceutical companies to understand the current development context and business environment in Singapore.

 

SIG Global Insight: Based in Singapore, Expanding Across Southeast Asia

 

 

During the thematic sharing session, SIG Global expert Lin Feng presented on “Based in Singapore, Expanding Across Southeast Asia — Opportunities in the Biopharmaceutical Market.” He highlighted Singapore’s unique advantages in terms of business environment, regional hub status, and policy support, while analyzing the immense potential and emerging trends in the Southeast Asian biopharmaceutical industry, providing valuable insights for companies pursuing international expansion.

In addition, Lin Feng drew on SIG Global’s real-world service cases to summarize four key models for Chinese companies going overseas, outlining their characteristics and actionable recommendations. This guidance helps enterprises translate their overseas expansion plans into practical, implementable strategies, offering clear direction for Xiamen biopharmaceutical companies in regional deployment.

Following this, Mr. Luo from Rongcheng Certified Public Accountants delivered a specialized session on “Chinese Companies Going to Southeast Asia: Global Structure Setup and Cross-Border Investment Tax Optimization.” He explored foundational yet often overlooked aspects of overseas expansion, including cross-border investment structures, tax compliance, and long-term development considerations.

Finally, Ms. Zhuang Bingli from the Xiamen Branch of Bank of Communications presented on “Navigating the Biopharmaceutical Seas with Bank of Communications: Cross-Border Settlement and Financial Support.” She introduced cross-border settlement solutions and financial support tailored to biopharmaceutical companies, providing practical backing for their international growth.

 

Roundtable Discussion & Interactive Exchange: From Trend Insights to Practical Experience

 

 

During the roundtable discussion, guests exchanged insights on the different stages and key considerations of overseas expansion:

• Qiu Shangzhen, Chairman of Linjia Group, shared from a corporate development perspective why going overseas is shifting from being an “optional strategy” to a “necessary choice.”
• Luo Wenlong, Secretary General of the Fujian Singaporean Association, shared practical insights on corporate financing and listing in Singapore based on his hands-on experience.
• Guan Xinxin, Founder of SIG Global, discussed how companies can build international brands after going overseas, sharing strategies for long-term planning and brand development.

These multidimensional insights resonated widely with the attending corporate representatives. During the interactive exchange, participants engaged deeply with the speakers on topics such as market entry, compliance arrangements, capital planning, and international brand building. The discussions were pragmatic and highly effective, reflecting the event’s original focus on practicality and implementable outcomes.

Overseas expansion for biopharmaceutical companies has never been an isolated choice; it is a systematic process driven by the coordination of the industrial chain, innovation chain, capital chain, and service chain. Singapore, with its robust institutional framework and strategic regional hub advantages, provides a critical foothold for companies.

SIG Global will continue to base itself in Singapore, working with partners to provide Chinese biopharmaceutical companies with professional, stable, and sustainable support for internationalization, helping enterprises advance steadily on their overseas expansion journey.